<DOC>
	<DOCNO>NCT02545504</DOCNO>
	<brief_summary>The primary objective study compare efficacy andecaliximab ( formerly GS-5745 ) versus placebo combination modify fluorouracil ( 5-FU ) , leucovorin ( LV ) , oxaliplatin ( OXA ) ( mFOLFOX6 ) measure overall survival .</brief_summary>
	<brief_title>Andecaliximab With mFOLFOX6 First Line Treatment Advanced Gastric Gastroesophageal Junction Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Key Adults histologically confirm adenocarcinoma stomach gastroesophageal junction inoperable , locally advanced metastatic amenable curative therapy Adequate hematologic , liver , coagulation kidney function Eastern Cooperative Oncology Group ( ECOG ) ≤ 1 Evaluable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) v 1.1 Key Previous chemotherapy locally advance metastatic gastric cancer . Human Epidermal Growth Factor Receptor 2 ( HER2 ) positive gastric cancer HIV , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) infection Pregnant breast feed woman Individuals know suspected central nervous system metastases individual require chronic daily treatment oral corticosteroid Grade ≥ 2 peripheral neuropathy Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gastroesophageal junction ( GEJ )</keyword>
	<keyword>Stomach cancer</keyword>
</DOC>